Syngene posts Rs 77.3 net profit in Q1FY22, gets boost from sales of COVID drug remdesivir

Syngene posts Rs 77.3 net profit in Q1FY22, gets boost from sales of COVID drug remdesivir Revenues rose 39 percent YoY to Rs 607 crore in Q1FY22 compared to Rs 437 crore in the corresponding period of the previous year.

No comments:

Post a Comment